Update on nephrogenic systemic fibrosis.

[1]  Raimund Erbel,et al.  Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. , 2009, Journal of the American College of Cardiology.

[2]  R. Lenkinski,et al.  Nephrogenic systemic fibrosis: a chemical perspective. , 2008, Radiology.

[3]  Diego R. Martín.  Nephrogenic system fibrosis: a radiologist's practical perspective. , 2008, European journal of radiology.

[4]  H. Thomsen,et al.  Extracellular Gd-CA: differences in prevalence of NSF. , 2008, European journal of radiology.

[5]  S. Morcos,et al.  Extracellular gadolinium contrast agents: differences in stability. , 2008, European journal of radiology.

[6]  J. L. Abraham,et al.  Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[7]  D. Broome,et al.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. , 2008, European journal of radiology.

[8]  D. Stenver.  Pharmacovigilance: what to do if you see an adverse reaction and the consequences. , 2008, European journal of radiology.

[9]  S. Cowper,et al.  Clinical and histological findings in nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[10]  L. Skov,et al.  Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. , 2008, Clinical nephrology.

[11]  H. Thomsen,et al.  High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.

[12]  E. Kanal,et al.  Gadolinium‐induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury , 2007, The British journal of dermatology.

[13]  L. Skov,et al.  Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long‐term persistence in nephrogenic systemic fibrosis , 2007, The British journal of dermatology.

[14]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  L. Chibnik,et al.  Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. , 2007, Arthritis and rheumatism.

[16]  Henrik S. Thomsen,et al.  Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents , 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

[17]  H. Thomsen.  ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis , 2007, European Radiology.

[18]  R. Johann-Liang,et al.  Safety risks with gadolinium‐based contrast agents , 2007, Journal of magnetic resonance imaging : JMRI.

[19]  H. Thomsen,et al.  Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? , 2007, Acta radiologica.

[20]  John Gosbee,et al.  ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.

[21]  C. Eken,et al.  Differences between various glomerular filtration rate calculation methods in predicting patients at risk for contrast-induced nephropathy. , 2007, The American journal of emergency medicine.

[22]  Tom Greene,et al.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. , 2007, Clinical chemistry.

[23]  J. Hollander,et al.  Discordance between serum creatinine and creatinine clearance for identification of ED patients with abdominal pain at risk for contrast-induced nephropathy. , 2007, The American journal of emergency medicine.

[24]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[25]  H. Thomsen.  Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide , 2006, European Radiology.

[26]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[27]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[28]  M. Tweedle,et al.  Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.

[29]  H. Thomsen,et al.  In which patients should serum creatinine be measured before iodinated contrast medium administration? , 2005, European Radiology.

[30]  H. Thomsen,et al.  Contrast media: interactions with other drugs and clinical tests , 2005, European Radiology.

[31]  L. V. Rao,et al.  Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. , 2004, American journal of clinical pathology.

[32]  M. Knopp,et al.  Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale. , 2003, Radiology.

[33]  K. Kent,et al.  Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.

[34]  F. Kronenberg,et al.  Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. , 2002, Journal of the American Society of Nephrology : JASN.

[35]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[36]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[37]  D. Leung,et al.  Gadolinium-based contrast agents in angiography and interventional radiology. , 1999, Radiologic clinics of North America.

[38]  David O. Cosgrove,et al.  Textbook of Contrast Media , 1999 .

[39]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[40]  P. Normann,et al.  Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. , 1995, Scandinavian journal of clinical and laboratory investigation.

[41]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[42]  S. H. Kim,et al.  The synthesis and evaluation of macrocyclic gadolinium-DTPA-bis(amide) complexes as magnetic resonance imaging contrast agents. , 1994, Investigative radiology.

[43]  E. Holtz,et al.  Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.

[44]  A. Sherry,et al.  Stability constants for Gd3+ binding to model DTPA‐conjugates and DTPA‐proteins: Implications for their use as magnetic resonance contrast agents , 1988, Magnetic resonance in medicine.

[45]  Henrik S. Thomsen,et al.  Contrast media : safety issues and ESUR guidelines , 2009 .

[46]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[47]  S. Cowper.  Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. , 2007, Advances in dermatology.

[48]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[49]  G. Krestin,et al.  Non-tissue Specific Extracellular MR Contrast Media , 2006 .

[50]  P. Goffette,et al.  Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography , 1999, European Radiology.

[51]  R. Agati,et al.  Trends in Contrast Media , 1999, Medical Radiology.

[52]  J. Desreux,et al.  Chemical Synthesis of Paramagnetic Complexes , 1999 .

[53]  W. Cacheris,et al.  The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.

[54]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .